Bayer seeks to reclaim losses from Chiron on Rapidpoint 400
This article was originally published in Clinica
Bayer is claiming that US biotechnology company Chiron failed to disclose technical faults associated with the Rapidpoint 400 blood gas analyser when Bayer acquired Chiron's diagnostics arm in 1998 (see Clinica No 826, p 1). Bayer recalled the product in early 1999, press reports state, and now, having relaunched the product, has filed suit in a Delaware district court (civil case 02-80). The claim for damages runs into several million dollars. The Wall Street Journal suggests a claim figure of $13.5 million.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.